Literature DB >> 12800146

Genomic imbalances in CML blast crisis: 8q24.12-q24.13 segment identified as a common region of over-representation.

Susan M Gribble1, Alistair G Reid, Ian Roberts, Colin Grace, Anthony R Green, Elizabeth P Nacheva.   

Abstract

The acute phase of chronic myeloid leukemia (CML) is accompanied by secondary chromosomal changes. The additional changes have a non-random pattern; however, highly abnormal (marker) chromosomes are reported in some 20% of abnormal karyotypes. These marker chromosomes have proved to be beyond the resolution of conventional G-banding analysis. We used molecular cytogenetic techniques to determine the structure of complex chromosome markers in 10 CML-derived cell lines after our investigations of CML patients in blast crisis. Multicolor fluorescence in situ hybridization identified a multitude of structural chromosome aberrations. In addition, genomic gains identified by comparative genomic hybridization (CGH) were mapped to highly complex marker chromosomes in more than one cell line. The most common genomic loss detected by CGH affected chromosome 9, whereas the most common genomic gains affected, in order of frequency, the sequences of 8q, 6, and 13q. The smallest discrete amplification on 8q was identified in cell line MEG-01. This amplicon contains sequences represented by the marker D8S263/RMC08P029 but did not contain the proximal MYC gene or a more distal marker, D8S256/RMC08P025. We determined the size of the amplicon to be less than the chromosome segment 8q24.12-q24.13. The use of region- and locus-specific probes to analyze the organization of highly complex marker structures aided the identification of preferentially amplified genomic regions. The resultant amplifications could harbor gene(s) driving disease progression. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12800146     DOI: 10.1002/gcc.10173

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  4 in total

1.  Overexpression of PRDM16 in the presence and absence of the RUNX1/PRDM16 fusion gene in myeloid leukemias.

Authors:  Sawcène Hazourli; Pierre Chagnon; Martin Sauvageau; Raouf Fetni; Lambert Busque; Josée Hébert
Journal:  Genes Chromosomes Cancer       Date:  2006-11       Impact factor: 5.006

2.  A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.

Authors:  Mario Notari; Paolo Neviani; Ramasamy Santhanam; Bradley W Blaser; Ji-Suk Chang; Annamaria Galietta; Anne E Willis; Denis C Roy; Michael A Caligiuri; Guido Marcucci; Danilo Perrotti
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

3.  Automated detection of residual cells after sex-mismatched stem-cell transplantation - evidence for presence of disease-marker negative residual cells.

Authors:  Jörn Erlecke; Isabell Hartmann; Martin Hoffmann; Torsten Kroll; Heike Starke; Anita Heller; Alexander Gloria; Herbert G Sayer; Tilman Johannes; Uwe Claussen; Thomas Liehr; Ivan F Loncarevic
Journal:  Mol Cytogenet       Date:  2009-05-29       Impact factor: 2.009

4.  FISH mapping of Philadelphia negative BCR/ABL1 positive CML.

Authors:  Anna Virgili; Diana Brazma; Alistair G Reid; Julie Howard-Reeves; Mikel Valgañón; Anastasios Chanalaris; Valeria As De Melo; David Marin; Jane F Apperley; Colin Grace; Ellie P Nacheva
Journal:  Mol Cytogenet       Date:  2008-07-18       Impact factor: 2.009

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.